Eris Lifesciences completed the acquisition of Indian branded formulations business unit of Biocon Biologics for $150m.

Eris Lifesciences, a pharmaceutical company, completed the acquisition of Indian branded formulations business unit of Biocon Biologics, an Indian biopharmaceutical company, for $150m. “This strategic collaboration with Eris Lifesciences for our portfolio of Metabolics, Oncology, and Critical Care products in India aligns with our commercial strategy to maximize patient reach and market potential. It builds on the success of our existing partnership with Eris for our Nephrology and Dermatology products and will allow us to deliver our high quality, lifesaving biosimilars to millions of patients in India. Biocon Biologics remains committed to a successful transition of employees of these business units, our product brands, and customers to ensure continuity for patients,” Shreehas Tambe, Biocon Biologics CEO & Managing Director.